Ctrl Worx Watch List › Company
ProtoKinetix, Inc. (PKTX): material weakness open at least 2,128 days
By Russell Tomoum, Ctrl Worx™. Built from its own SEC filings. How the Clock works.
ProtoKinetix, Inc. reported ineffective internal control over financial reporting because of a material weakness in 6 filings since Mar 5, 2021. The latest was its 10-K for the period ended Dec 31, 2025.
Ctrl Worx Watch List™ status
On the ClockStill filing, and no annual report of its own says the weakness is fixed.
Checked against SEC EDGAR: Oct 29, 2026 · Entry #10399
Causes the company named
Segregation of duties · 6Entity-level and governance · 6Financial close and reporting · 5
Insufficient segregation of duties due to limited personnel and inadequate governance documentation processes.
What the latest filing says
Material Weaknesses Identified In connection with the preparation of our financial statements for the year ended December 31, 2025, certain significant deficiencies in internal control became evident to management that, in the aggregate, represent material weaknesses, which include the following: Insufficient segregation of duties in our finance and accounting functions due to limited personnel. During the year ended December 31, 2025, we used outside services to perform all aspects of our financial reporting process, including, but not limited to, access to the underlying accounting records and systems, the ability to post and record journal entries and responsibility for the preparation of the financial statements. This creates a lack of review over the financial reporting process that would likely result in a failure to detect errors in spreadsheets, calculations, or assumptions used to compile the financial statements and related disclosures as filed with the SEC. These control deficiencies could result in a material misstatement to our interim or annual financial statements that [...]
From the controls section of the 10-K filed Sep 3, 2026. Read the full filing on SEC EDGAR.
Company response: ProtoKinetix, Inc. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.
Filings
| Filed | Form | Period | Controls | Causes | Filing |
|---|---|---|---|---|---|
| Sep 3, 2026 | 10-K | Dec 31, 2025 | Not effective | Segregation of duties; Financial close and reporting; Entity-level and governance | EDGAR |
| Mar 28, 2025 | 10-K | Dec 31, 2024 | Not effective | Segregation of duties; Entity-level and governance | EDGAR |
| Mar 20, 2024 | 10-K | Dec 31, 2023 | Not effective | Segregation of duties; Financial close and reporting; Entity-level and governance | EDGAR |
| Mar 17, 2023 | 10-K | Dec 31, 2022 | Not effective | Segregation of duties; Financial close and reporting; Entity-level and governance | EDGAR |
| Mar 10, 2022 | 10-K | Dec 31, 2021 | Not effective | Segregation of duties; Financial close and reporting; Entity-level and governance | EDGAR |
| Mar 5, 2021 | 10-K | Dec 31, 2020 | Not effective | Segregation of duties; Financial close and reporting; Entity-level and governance | EDGAR |
Others on the Clock in the same industry
By SEC industry code: 2834, Pharmaceutical Preparations, then related codes.
- BIOADAPTIVES, INC. (BDPT) · open since Dec 2020 or earlier
- BIOXYTRAN, INC (BIXT) · open since Dec 2020 or earlier
- Celularity Inc (CELU) · open since Dec 2020 or earlier
- CHINA PHARMA HOLDINGS, INC. (CPHI) · open since Dec 2020 or earlier
- Clene Inc. (CLNN) · open since Dec 2020 or earlier
Follow PKTX for free
Get an email when ProtoKinetix, Inc files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.
Want the next one the day it's filed?
MW Pro sends an alert the day a company you follow reports a material weakness or says it fixed one. Founding price $990 a year.
Join the MW Pro waitlistLook up any company in Controls Radar™Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with ProtoKinetix, Inc. or the SEC. Not investment advice. Why you can rely on the Watch List.